Breyanzi

Bristol Myers angles Breyanzi for another blood cancer as it works to close Gilead's CAR-T lead
Fierce Pharma
Mon, 02/10/25 - 10:14 am
Bristol Myers Squibb
Breyanzi
CAR-T
marginal zone lymphoma
Gilead Sciences
Bristol Myers faces renewed, $6.7 billion lawsuit over delayed cancer drug
Yahoo/Reuters
Thu, 11/14/24 - 11:06 pm
Bristol Myers Squibb
Celgene
legal
Breyanzi
Allogene abandons leukemia plans for CAR-T in wake of Breyanzi approval
Fierce Biotech
Thu, 11/14/24 - 11:14 am
Allogene
CAR-T
Breyanzi
cema-cel
relapsed or refractory chronic lymphocytic leukemia
Bristol Myers beats $6.4 billion lawsuit over delayed cancer drug
Reuters
Tue, 10/1/24 - 09:59 am
Bristol Myers Squibb
Celgene
Breyanzi
legal
3 Big Pharma cancer drugs facing inflation penalties
Pharma Voice
Wed, 07/31/24 - 10:27 am
inflation
Inflation Reduction Act
drug pricing
Abecma
Breyanzi
Bristol Myers Squibb
Pfizer
Adcetris
Astellas
Padcev
cancer
Bristol Myers secures another FDA go-ahead for Breyanzi, this time in mantle cell lymphoma
Fierce Pharma
Thu, 05/30/24 - 11:10 pm
Bristol Myers Squibb
Breyanzi
FDA
mantle cell lymphoma
FDA approves expanded use of Bristol Myers' cancer cell therapy
Reuters
Wed, 05/15/24 - 10:48 pm
Brisstol Myers Squibb
cell therapy
Breyanzi
follicular lymphoma
BMS’s Breyanzi Becomes First CAR-T Therapy for Two Types of Leukemia
BioSpace
Fri, 03/15/24 - 11:32 am
Bristol Myers Squibb
CAR-T
CLL
Breyanzi
FDA
JNJ
Carvykti
ASCO: BMS pitches Breyanzi as the first CAR-T for CLL. But will a single-arm trial persuade the FDA?
Fierce Pharma
Fri, 05/26/23 - 09:57 am
ASCO 2023
Bristol Myers Squibb
Breyanzi
CAR-T
CLL
SLL
clinical trials
Bristol Myers dodges one $6.4B Celgene buyout CVR suit, but the battle is far from over
Fierce Pharma
Thu, 03/2/23 - 10:45 pm
Bristol Myers Squibb
Breyanzi
Celgene
legal
M&A
CVRs
Bristol Myers claims win with CAR-T therapy Breyanzi in leukemia
Endpoints
Thu, 01/26/23 - 05:09 pm
Bristol Myers Squibb
CAR-T
Breyanzi
CLL
cell therapy
ASH: Bristol Myers bolsters Breyanzi's case in earlier lymphoma amid clash with Gilead
Fierce Pharma
Mon, 12/12/22 - 10:16 am
Bristol Myers Squibb
Breyanzi
B-cell lymphoma
CAR-T
ASH 2022
Even as Revlimid's star fades, Bristol Myers' core offerings have reached a 'critical mass,' CEO says
Fierce Pharma
Thu, 10/27/22 - 11:04 am
Bristol Myers Squibb
generics
Revlimid
Abecma
Breyanzi
Pharma CEOs
Giovanni Caforio
Federal judge denies Bristol Myers' attempt to avoid Celgene shareholder lawsuit
Endpoints
Mon, 06/27/22 - 07:02 pm
Celgene
Bristol Myers Squibb
Breyanzi
legal
Amidst Legal Battle, BMS' CAR-T Therapy Scores Second FDA Approval
BioSpace
Mon, 06/27/22 - 06:32 pm
Bristol Myers Squibb
CAR-T
Breyanzi
liso-cel
FDA
large B-cell lymphoma
'Major blunder:' Ex-staffers blast Bristol Myers Squibb's handling of Breyanzi approval in latest CVR lawsuit update
Fierce Pharma
Wed, 02/23/22 - 10:09 pm
Bristol Myers Squibb
legal
Breyanzi
shareholders
CAR-T
liso-cel
lymphoma
Bristol busy boosting supply of Breyanzi, Abecma as massive Revlimid patent cliff looms
Fierce Pharma
Fri, 02/4/22 - 11:22 am
Bristol Myers Squibb
CAR-T
Breyanzi
Abecma
JPM 2022: Bristol Myers plots 3 blockbuster launches to counter Revlimid's patent cliff
Fierce Pharma
Mon, 01/10/22 - 11:49 pm
JPMHC 2022
Bristol Myers Squibb
Revlimid
patent cliffs
Opdivo
Eliquis
Reblozyl
Breyanzi
ASH: Bristol Myers' Breyanzi, Gilead's Yescarta lock horns in race to move CAR-T therapy to earlier lymphoma
Fierce Pharma
Sat, 12/11/21 - 09:22 pm
Gilead Sciences
Yescarta
Bristol Myers Squibb
Breyanzi
CAR-T
lymphoma
BMS will file for earlier-line use of Breyanzi in lymphoma after trial win
Pharmaforum
Fri, 06/11/21 - 10:49 am
Bristol Myers Squibb
CAR-T
Breyanzi
large B-cell lymphoma
Novartis
Gilead Sciences
FDA

Pages